Introduction
An uncommon location for gliomas is the occipital lobe, in which the incidence ranges from 5% to 10% in several series. Patients with occipital lobe gliomas typically present with seizures but can have more subtle deficits in visual fields and neurocognitive function, including attention, proprioception, reading, and writing. , Moreover, dominant hemisphere lesions can be in close juxtaposition to language-associated white matter tracts, in which surgery can be associated with significant morbidity. , In this chapter, we present a case of a dominant hemisphere occipital high-grade glioma.
Chief complaint: right-sided vision loss and difficulty speaking
History of present illness
A 73-year-old, right-handed woman with a history of hypertension, hypercholesterolemia, and asthma presented with progressive right-sided vision loss and difficulty speaking. She was seen by her primary care physician when she stated she noticed having a blind spot on the right side when she was at a four-way intersection. In addition, she complains of difficulty with word pronunciation ( Fig. 25.1 ).
Medications : Lisinopril, fluticasone, simvastatin.
Allergies : No known drug allergies.
Past medical and surgical history : Hypertension, hypercholesterolemia, asthma, right knee replacement.
Family history : No history of intracranial malignancies.
Social history : Retired teacher, no smoking, social alcohol.
Physical examination : Awake, alert, oriented to person, place, and time; Language: intact naming and repetition but with slight dysarthria; Cranial nerves II to XII intact except right homonymous hemianopsia; No drift, moves all extremities with full strength.
Imaging : Chest/abdomen/pelvis with no evidence of primary disease.

Bob S. Carter, MD, PhD, Massachusetts General Hospital, Boston, MA, United States | Sunit Das, MD, PhD, St. Michael’s Hospital, University of Toronto, Toronto, Canada | Maciej S. Lesniak, MD, Northwestern University, Chicago, IL, United States | Jinsong Wu, MD, PhD, Fudan University, Huashan Hospital, Shanghai, China | |
---|---|---|---|---|
Preoperative | ||||
Additional tests requested | None | Visual field testing | Visual field testing | Tasked-based BOLD DTI MRS PWI Neuropsychological assessment |
Surgical approach selected | Left occipital craniotomy with 5-ALA | Left temporo-occipital craniotomy | Left occipital craniotomy | Left parietal needle biopsy (because of age) |
Anatomic corridor | Occipital-parietal | Occipital–lingual gyrus | Occipital | Angular gyrus, IPL |
Goal of surgery | Diagnosis, debulking | Resection of contrast-enhancing portion | Resection of contrast-enhancing portion | Diagnosis |
Perioperative | ||||
Positioning | Left lateral | Left lateral | Left park bench | Prone with 30-degree left rotation |
Surgical equipment | Surgical navigation Surgical microscope with 5-ALA Ultrasonic aspirator | Surgical navigation Ultrasound Surgical microscope Ultrasonic aspirator | Surgical navigation Surgical microscope | Surgical navigation Needle biopsy kit |
Medications | 5-ALA Mannitol, furosemide Antiepileptics | Steroids | Mannitol Steroids | Steroids Antiepileptics |
Anatomic considerations | Posterior corpus callosum | Visual pathways, corpus callosum, ventricle | Motor and visual cortex, visual fields | Angular gyrus, STG/MTG, optic radiations, IFOF, splenium, major forceps of corpus callosum, precuneus, cuneus, parieto-occipital sulcus |
Complications feared with approach chosen | Speech deficits | Visual deficit | Visual and motor deficit | Hemorrhage |
Intraoperative | ||||
Anesthesia | General | General | General | General |
Skin incision | U-shaped | Horseshoe | Linear | Linear |
Bone opening | Left parieto-occipital | Left temporo-occipital | Left occipital | Left parietal (burr hole) |
Brain exposure | Left parieto-occipital | Left temporo-occipital | Left occipital | Angular gyrus |
Method of resection | Craniotomy based on navigation, dural opening, trans parieto-occipital based on navigation using shortest distance, internal debulking, resect residual with 5-ALA, anticipate residual anteriorly near corpus callosum | Craniotomy based on navigation, flap designed based on axial planes, ultrasound to visualize most superficial portion of tumor to cortical surface, dural opening, corticectomy based on ultrasound, surgical microscope to dissect through white matter, internal debulking and working to the edges using ultrasound and microscope, dural tack up sutures | Craniotomy based on navigation, determine shortest distance based on navigation, internal debulking under microscopic visualization, minimize retraction, resection of enhancing portion | Trajectory based on navigation, burr hole, dural opening over angular gyrus, targeting three sites within lesion, four samples from each target point |
Complication avoidance | Internal debulking, 5-ALA, anticipate anterior residual | Internal debulking | Internal debulking | Angular gyrus starting point, needle biopsy |
Postoperative | ||||
Admission | ICU | ICU | ICU | ICU |
Postoperative complications feared | Expect visual deficit, speech deficit | Visual deficit, CSF leak | Visual deficit, seizure | Hemorrhage |
Follow-up testing | MRI within 48 hours after surgery | MRI within 48 hours after surgery | CT within 12 hours after surgery MRI within 48 hours after surgery | CT head immediately after surgery |
Follow-up visits | 7–10 days after surgery | 1 month after surgery | 14 days after surgery | 1 month after surgery |
Adjuvant therapies recommended | ||||
IDH status | Mutant–radiation/temozolomide Wild type–radiation/temozolomide | Mutant–radiation/temozolomide Wild type–radiation/temozolomide | Mutant–radiation/temozolomide + TTF Wild type–radiation/temozolomide + TTF | Mutant–radiation/ temozolomide Wild type–radiation/temozolomide |
MGMT status | Methylated–radiation/temozolomide Unmethylated–radiation/temozolomide | Methylated–radiation/temozolomide Unmethylated–radiation/temozolomide | Methylated–radiation/temozolomide + TTF Unmethylated–radiation/temozolomide + TTF | Methylated–temozolomide Unmethylated–radiation/ temozolomide |

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree


